Expansion of Sartorius Stedim Cellca
Hugo de Wit, Cellca.
Laboratory and office facility to be constructed on the site by 2019.
Sartorius Stedim Cellca based near Ulm in southern Germany, continues on the growth track. At the end of November, the company in its 11th year since its founding purchased property of more than 6,000 square meters at Ulm’s Science Park III at Eselsberg to build a new laboratory and office complex. The new facility, which will approximately double the company’s space, is scheduled to be completed by the end of 2019. So far, Sartorius Stedim Cellca has been located in a rented building in Laupheim.
“Our new site’s proximity to universities and research institutes in Ulm’s Scientific Park offers an excellent environment to promote our growing business for which we are also seeking additional highly qualified staff,“ commented Managing Director Hugo de Wit. “Besides the advantages offered by this research environment, its conveniently accessible location was also decisive for us. We need to be within easy reach of our international customers,” continued de Wit.
Sartorius Stedim Cellca develops and markets platform technologies, such as cell lines and associated services, for customers in the biopharmaceutical industry. Since 2015, the company has been part of the biopharma supplier Sartorius Stedim Biotech and currently employs 80 people.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.